Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving.

Selby P, Andriash K, Zawertailo L, Persad D, Zack M, Busto UE.

J Clin Psychopharmacol. 2013 Oct;33(5):667-74. doi: 10.1097/JCP.0b013e31829a829d.

PMID:
23963055
2.

Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.

Le Foll B, Guranda M, Wilson AA, Houle S, Rusjan PM, Wing VC, Zawertailo L, Busto U, Selby P, Brody AL, George TP, Boileau I.

Neuropsychopharmacology. 2014 Jan;39(2):415-24. doi: 10.1038/npp.2013.209. Epub 2013 Aug 19.

3.

Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-(+)-PHNO PET study.

Chiuccariello L, Boileau I, Guranda M, Rusjan PM, Wilson AA, Zawertailo L, Houle S, Busto U, Le Foll B.

PLoS One. 2013;8(3):e60382. doi: 10.1371/journal.pone.0060382. Epub 2013 Mar 29.

4.

Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats.

Sotomayor-Zárate R, Gysling K, Busto UE, Cassels BK, Tampier L, Quintanilla ME.

Psychopharmacology (Berl). 2013 May;227(2):287-98. doi: 10.1007/s00213-013-2974-3. Epub 2013 Jan 24.

PMID:
23344555
5.

Effects of stress and alcohol cues in men with and without problem gambling and alcohol use disorder.

Steinberg L, Tremblay AM, Zack M, Busto UE, Zawertailo LA.

Drug Alcohol Depend. 2011 Dec 1;119(1-2):46-55. doi: 10.1016/j.drugalcdep.2011.05.011. Epub 2011 Jun 11.

PMID:
21658863
6.

Stress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkers.

Zack M, Woodford TM, Tremblay AM, Steinberg L, Zawertailo LA, Busto UE.

Neuropsychopharmacology. 2011 Jan;36(2):445-58. doi: 10.1038/npp.2010.177. Epub 2010 Oct 6. Erratum in: Neuropsychopharmacology. 2011 Jan;36(2):549.

7.

Enhanced smoking cue salience associated with depression severity in nicotine-dependent individuals: a preliminary fMRI study.

Kushnir V, Menon M, Balducci XL, Selby P, Busto U, Zawertailo L.

Int J Neuropsychopharmacol. 2013 Jun;16(5):997-1008. doi: 10.1017/S1461145710000696. Epub 2010 Jul 7.

PMID:
20604987
8.

Pediatric cancer rates after universal folic acid flour fortification in Ontario.

Grupp SG, Greenberg ML, Ray JG, Busto U, Lanctôt KL, Nulman I, Koren G.

J Clin Pharmacol. 2011 Jan;51(1):60-5. doi: 10.1177/0091270010365553. Epub 2010 May 10.

PMID:
20457589
9.

Cocaine and amphetamine regulated transcript (CART) gene in the comorbidity of schizophrenia with alcohol use disorders and nicotine dependence.

Busto A, Souza RP, Lobo DS, Shaikh SA, Zawertailo LA, Busto UE, Kennedy JL.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):834-6. doi: 10.1016/j.pnpbp.2010.03.030. Epub 2010 Mar 30.

PMID:
20362026
10.

Comorbidity between bipolar disorder and alcohol use disorder: association of dopamine and serotonin gene polymorphisms.

Yasseen B, Kennedy JL, Zawertailo LA, Busto UE.

Psychiatry Res. 2010 Mar 30;176(1):30-3. doi: 10.1016/j.psychres.2008.12.009. Epub 2010 Jan 13.

PMID:
20071033
11.

Effect of metabolic blockade on the psychoactive effects of dextromethorphan.

Zawertailo LA, Tyndale RF, Busto U, Sellers EM.

Hum Psychopharmacol. 2010 Jan;25(1):71-9. doi: 10.1002/hup.1086.

PMID:
20041473
12.

The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers.

Hussain S, Zawertailo L, Busto U, Zack M, Farvolden P, Selby P.

Addict Behav. 2010 Feb;35(2):164-7. doi: 10.1016/j.addbeh.2009.09.004. Epub 2009 Sep 14.

PMID:
19836144
13.

Dopaminergic activity in depressed smokers: a positron emission tomography study.

Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA.

Synapse. 2009 Aug;63(8):681-9. doi: 10.1002/syn.20646.

14.

Apathy associated with Alzheimer disease: use of dextroamphetamine challenge.

Lanctôt KL, Herrmann N, Black SE, Ryan M, Rothenburg LS, Liu BA, Busto UE.

Am J Geriatr Psychiatry. 2008 Jul;16(7):551-7. doi: 10.1097/JGP.0b013e318170a6d1.

PMID:
18591575
15.

Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.

Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL.

J Clin Psychopharmacol. 2008 Jun;28(3):296-301. doi: 10.1097/JCP.0b013e318172b479.

PMID:
18480686
16.

Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial.

Glass JR, Sproule BA, Herrmann N, Busto UE.

J Clin Psychopharmacol. 2008 Apr;28(2):182-8. doi: 10.1097/JCP.0b013e31816a9e4f.

PMID:
18344728
17.

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE.

BMJ. 2005 Nov 19;331(7526):1169. Epub 2005 Nov 11. Review.

18.

Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe.

Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE.

Arch Gen Psychiatry. 2005 Nov;62(11):1228-36.

PMID:
16275810
19.

Prescription opioid abuse in patients presenting for methadone maintenance treatment.

Brands B, Blake J, Sproule B, Gourlay D, Busto U.

Drug Alcohol Depend. 2004 Feb 7;73(2):199-207.

PMID:
14725960
20.

Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET.

Cárdenas L, Houle S, Kapur S, Busto UE.

Synapse. 2004 Jan;51(1):27-31.

PMID:
14579423
21.

Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.

Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM.

J Clin Psychopharmacol. 2003 Jun;23(3):269-80.

PMID:
12826989
22.

Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects.

Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE.

J Clin Psychopharmacol. 2003 Jun;23(3):260-8.

PMID:
12826988
23.

The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo.

Gafni I, Busto UE, Tyndale RF, Kaplan HL, Sellers EM.

J Clin Psychopharmacol. 2003 Apr;23(2):169-75.

PMID:
12640218
24.

Nicotine patches and the subjective effects of cigarette smoking: a pilot study.

Cárdenas L, Busto UE, MacDonald A, Corrigall WA.

Can J Clin Pharmacol. 2002 Winter;9(4):175-82.

PMID:
12584575
25.

Brain reward system activity in major depression and comorbid nicotine dependence.

Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE.

J Pharmacol Exp Ther. 2002 Sep;302(3):1265-71.

PMID:
12183688
26.

Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine.

Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE.

Arch Gen Psychiatry. 2002 May;59(5):409-16.

PMID:
11982444
27.

Use of prescription and nonprescription hypnotics in a Canadian elderly population.

Busto UE, Sproule BA, Knight K, Herrmann N.

Can J Clin Pharmacol. 2001 Winter;8(4):213-21.

PMID:
11743594
28.

The role of the brain reward system in depression.

Naranjo CA, Tremblay LK, Busto UE.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):781-823. Review.

PMID:
11383978
29.

Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.

Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):460-5.

PMID:
11259331
30.

A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.

Busto UE, Kaplan HL, Wright CE, Gomez-Mancilla B, Zawertailo L, Greenblatt DJ, Sellers EM.

J Clin Psychopharmacol. 2000 Dec;20(6):628-35.

PMID:
11106134
31.

Comparative abuse liability of intravenously administered remifentanil and fentanyl.

Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM.

J Clin Psychopharmacol. 2000 Dec;20(6):597-606.

PMID:
11106130
32.

Pharmacogenetics of alcohol: treatment implications.

Busto UE.

Alcohol Clin Exp Res. 2000 Sep;24(9):1323-6. No abstract available.

PMID:
11003196
33.

Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.

Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Säwe J, Tyndale RF, Sellers EM.

J Clin Psychopharmacol. 2000 Aug;20(4):435-44.

PMID:
10917405
34.

Long-term benzodiazepine therapy does not result in brain abnormalities.

Busto UE, Bremner KE, Knight K, terBrugge K, Sellers EM.

J Clin Psychopharmacol. 2000 Feb;20(1):2-6.

PMID:
10653201
35.

Benzodiazepines: the science and the myths.

Busto UE.

Can J Clin Pharmacol. 1999 Winter;6(4):185-6. Review. No abstract available.

PMID:
10601751
36.

The effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study.

Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, Naranjo CA, Shear NH.

J Clin Psychiatry. 1999 Oct;60(10):690-7.

PMID:
10549686
37.

The use of non-prescription sleep products in the elderly.

Sproule BA, Busto UE, Buckle C, Herrmann N, Bowles S.

Int J Geriatr Psychiatry. 1999 Oct;14(10):851-7.

PMID:
10521884
38.

Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing.

Busto UE, Zawertailo LA, Kaplan HL, Sellers EM.

Can J Clin Pharmacol. 1999 Summer;6(2):103-10.

PMID:
10519736
39.

Risk of drug dependence and abuse posed by barbiturate-containing analgesics.

Sellers EM, Hoornweg K, Busto UE, Romach MK.

Can J Clin Pharmacol. 1999 Spring;6(1):18-25. Review.

PMID:
10465862
40.

Long-term codeine use is associated with depressive symptoms.

Romach MK, Sproule BA, Sellers EM, Somer G, Busto UE.

J Clin Psychopharmacol. 1999 Aug;19(4):373-6.

PMID:
10440467
41.

Characteristics of dependent and nondependent regular users of codeine.

Sproule BA, Busto UE, Somer G, Romach MK, Sellers EM.

J Clin Psychopharmacol. 1999 Aug;19(4):367-72.

PMID:
10440466
42.

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.

Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM.

J Clin Psychopharmacol. 1998 Aug;18(4):332-7.

PMID:
9690700
43.

A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.

Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM.

J Clin Psychopharmacol. 1998 Apr;18(2):121-31.

PMID:
9555597
44.

The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis.

Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctôt KL, Liu BA, Shulman KI, Silver IL, Narango CA, Shear NH.

J Affect Disord. 1997 Dec;46(3):191-217.

PMID:
9547117
45.

Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.

Busto UE, Naranjo CA, Bremner KE, Peachey JE, Bologa M.

J Psychiatry Neurosci. 1998 Jan;23(1):35-44.

46.

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM.

J Pharmacol Exp Ther. 1997 Apr;281(1):103-8.

PMID:
9103485
47.

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Ozdemir V, Fourie J, Busto U, Naranjo CA.

Clin Pharmacokinet. 1996 Nov;31(5):372-85. Review.

PMID:
9118585
48.

Benzodiazepine use in Chile: impact of availability on use, abuse, and dependence.

Busto UE, Ruiz I, Busto M, Gacitúa A.

J Clin Psychopharmacol. 1996 Oct;16(5):363-72.

PMID:
8889908
49.
50.

Clinical aspects of chronic use of alprazolam and lorazepam.

Romach M, Busto U, Somer G, Kaplan HL, Sellers E.

Am J Psychiatry. 1995 Aug;152(8):1161-7.

PMID:
7625464

Supplemental Content

Support Center